Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.52 |
| ▸ | ACVR1 | Q04771 | 6/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 6/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.37 |
| ▸ | PRKCA | P17252 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31095355 | 1.00 | ADORA2A (0.52) | ADORA2AADORA1ADORA3ADORA2BACVR1 | |
| SCHEMBL20589377 | 1.00 | ADORA2A (0.52) | ADORA2AADORA1ADORA3ADORA2BACVR1 | |
| SCHEMBL25265995 | 0.76 | ACVR1 (0.73) | ADORA2AADORA1ADORA3ADORA2BACVR1 | |
| SCHEMBL25202221 | 0.76 | ACVR1 (0.73) | ADORA2AADORA1ADORA3ADORA2BACVR1 | |
| SCHEMBL5672002 | 0.74 | CHRNA7 (0.54) | PDE10ACCNE2CDK4CCND1CCNE1 | |
| SCHEMBL5672184 | 0.74 | CHRNA7 (0.54) | PDE10ACCNE2CDK4CCND1CCNE1 | |
| SCHEMBL31095255 | 0.72 | RAB9A (0.50) | ADORA2AADORA1AURKBPDE4DPDE4A | |
| SCHEMBL25513879 | 0.72 | RAB9A (0.50) | ADORA2AADORA1AURKBPDE4DPDE4A | |
| SCHEMBL3678922 | 0.71 | ADORA2A (0.70) | ADORA2AADORA1ADORA3ADORA2BACVR1 | |
| SCHEMBL3678925 | 0.71 | ADORA2A (0.70) | ADORA2AADORA1ADORA3ADORA2BACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376117-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-11-14 | — | — | US | disclosed |
| US-12054492-B2 | Imidazole-containing inhibitors of ALK2 kinase | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-20230271975-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-08-31 | — | — | US | disclosed |
| US-20230271975-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-08-31 | — | — | US | disclosed |
| US-20230271975-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-08-31 | — | — | US | disclosed |
| US-11661426-B2 | Imidazole-containing inhibitors of ALK2 kinase | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661426-B2 | Imidazole-containing inhibitors of ALK2 kinase | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661426-B2 | Imidazole-containing inhibitors of ALK2 kinase | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20220332723-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2022-10-20 | — | — | US | disclosed |
| EP-3638229-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | Biocryst Pharmaceuticals, Inc. (US) | 2020-04-22 | — | — | EP | disclosed |
| WO-2018232094-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | BIOCRYST PHARMACEUTICALS, INC. (US) | 2018-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271975-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | ALK, ACVR2B, ACVR2A | ADORA2A 3254/4885ADORA1 3027/4885ADORA3 2884/4885 |
| US-11661426-B2 | Imidazole-containing inhibitors of ALK2 kinase | ALK, ACVR2B, ACVR2A | ADORA2A 3254/4885ADORA1 3027/4885ADORA3 2884/4885 |
| US-20240376117-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | ALK, ACVR2B, ACVR2A | ADORA2A 3254/4885ADORA1 3027/4885ADORA3 2884/4885 |
| US-20220332723-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | ALK, ACVR2B, ACVR2A | ADORA2A 3254/4885ADORA1 3027/4885ADORA3 2884/4885 |
| US-12054492-B2 | Imidazole-containing inhibitors of ALK2 kinase | ALK, ACVR2B, ACVR2A | ADORA2A 3254/4885ADORA1 3027/4885ADORA3 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.